Working Group 5

Clinical Trials on Rare Gynaecological Cancer

Main Objective

Coordination of interactions between clinical trials, translational research, and basic research. This will be an opportunity to track the activities in the clinical validation of therapeutic approaches and to reassemble the key research lines, to be aligned with the
capacity, insights, and knowledge of the other stakeholder in the Action. This is highly important to maintain continuity and expedience of clinical and patient-relevant research and development. 


a) To carry out discussion of new clinical trial related activities i.e. trials, translational research, biobanking, and others;

b) To create specific spaces for the interaction of researchers with patients' advocacy group, industry, governmental bodies and other key relevant stakeholders.

For more information, please contact the WG 5 Leader:

Dr Klejda Harasani on